



*In Search of Excellence*

## ORION PHARMA LIMITED

Registered Office: Orion House, 153-154 Tejgaon I/ A,  
Tejgaon, Dhaka-1208

### UN-AUDITED THIRD QUARTERLY (Q3) FINANCIAL STATEMENTS

This is for the information of all concerned that the un-audited condensed consolidated financial statements of **Orion Pharma Limited** as on and for the **Third Quarterly (Q3) period ended on March 31, 2021**, has been adopted by the Board of Directors in its meeting held on **June 30, 2021**. The excerpts of the Financial Statements are as follows:

		March 31, 2021		March 31, 2020	
Consolidated NAV per Share - Q3 (Including Revaluation Surplus)	:	BDT. 78.78		BDT. 76.68	
Consolidated NAV per Share - Q3 (Excluding Revaluation Surplus)	:	BDT. 70.79		BDT. 68.57	
		July 01, 2020 to March 31, 2021	July 01, 2019 to March 31, 2020	Jan 01, 2021 to March 31, 2021	Jan 01, 2020 to March 31, 2020
Consolidated Earnings Per Share (EPS)- Q3	:	BDT. 2.98	BDT. 2.75	BDT. 0.95	BDT. 0.61
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q3	:	BDT. 7.52	BDT. 2.73	----	----

The Detailed Financial Statements are also available in the Company's website: [www.orionpharmabd.com](http://www.orionpharmabd.com).

Sd/-  
Company Secretary

Sd/-  
Chief Financial Officer

Sd/-  
Director

Dated: Dhaka  
June 30, 2021

Sd/-  
Managing Director

Sd/-  
Chairman